Neutrophils in type 1 diabetes

Journal of Diabetes Investigation

Volumn 7, Issue 5, 2016, Pages 652-663

  Huang, Juan ^a   Xiao, Yang ^a   Xu, Aimin ^b   Zhou, Zhiguang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Immune cells; Neutrophils; Type 1 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BETA1 INTEGRIN; CD18 ANTIGEN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 6; L SELECTIN; LEUKOCYTE ELASTASE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MYELOPEROXIDASE; PADGEM PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

CD8+ T LYMPHOCYTE; CELL ADHESION; CELL AGGREGATION; CELL INTERACTION; CELL MIGRATION; CYTOKINE PRODUCTION; DISEASE COURSE; DOWN REGULATION; ENDOTHELIUM CELL; EXTRACELLULAR TRAP; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTE FUNCTION; NEUTROPHIL; NEUTROPHIL COUNT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; THROMBOCYTE COUNT; UPREGULATION;

EID: 84991042545     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12469     Document Type: Review

References (129)

1. Borregaard N, Lollike K, Kjeldsen L, et al. Human neutrophil granules and secretory vesicles. Eur J Haematol 1993; 51: 187–198.
2. Borregaard N. Neutrophils, from marrow to microbes. Immunity 2010; 33: 657–670.
3. Amulic B, Cazalet C, Hayes GL, et al. Neutrophil function: from mechanisms to disease. Annu Rev Immunol 2012; 30: 459–489.
4. Brown KA, Brain SD, Pearson JD, et al. Neutrophils in development of multiple organ failure in sepsis. Lancet 2006; 368: 157–169.
5. Mayadas TN, Cullere X, Lowell CA. The multifaceted functions of neutrophils. Annu Rev Pathol 2014; 9: 181–218.
6. Mantovani A, Cassatella MA, Costantini C, et al. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011; 11: 519–531.
7. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006; 6: 173–182.
8. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973–977.
9. Mocsai A. Diverse novel functions of neutrophils in immunity, inflammation, and beyond. J Exp Med 2013; 210: 1283–1299.
10. Kessenbrock K, Krumbholz M, Schonermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15: 623–625.
11. Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011; 187: 538–552.
12. Naegele M, Tillack K, Reinhardt S, et al. Neutrophils in multiple sclerosis are characterized by a primed phenotype. J Neuroimmunol 2012; 242: 60–71.
13. Collier A, Jackson M, Bell D, et al. Neutrophil activation detected by increased neutrophil elastase activity in type 1 (insulin-dependent) diabetes mellitus. Diabetes Res 1989; 10: 135–138.
14. Jackson MH, Collier A, Nicoll JJ, et al. Neutrophil count and activation in vascular disease. Scott Med J 1992; 37: 41–43.
15. Valle A, Giamporcaro GM, Scavini M, et al. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes 2013; 62: 2072–2077.
16. Harsunen MH, Puff R, D'Orlando O, et al. Reduced blood leukocyte and neutrophil numbers in the pathogenesis of type 1 diabetes. Horm Metab Res 2013; 45: 467–470.
17. Wang Y, Xiao Y, Zhong L, et al. Increased neutrophil elastase and proteinase 3 and augmented NETosis are closely associated with beta-cell autoimmunity in patients with type 1 diabetes. Diabetes 2014; 63: 4239–4248.
18. Battaglia M. Neutrophils and type 1 autoimmune diabetes. Curr Opin Hematol 2014; 21: 8–15.
19. Debczynski W, Pietruska Z. [Chemotaxis and spontaneous migration of neutrophil leukocytes from patients with diabetes]. Pol Tyg Lek 1994; 49: 11–13.
20. Valerius NH, Eff C, Hansen NE, et al. Neutrophil and lymphocyte function in patients with diabetes mellitus. Acta Med Scand 1982; 211: 463–467.
21. Kelly MK, Brown JM, Thong YH. Neutrophil and monocyte adherence in diabetes mellitus, alcoholic cirrhosis, uraemia and elderly patients. Int Arch Allergy Appl Immunol 1985; 78: 132–138.
22. Cutler CW, Eke P, Arnold RR, et al. Defective neutrophil function in an insulin-dependent diabetes mellitus patients. A case report. J Periodontol 1991; 62: 394–401.
23. Wilson RM, Reeves WG. Neutrophil phagocytosis and killing in insulin-dependent diabetes. Clin Exp Immunol 1986; 63: 478–484.
24. Marhoffer W, Stein M, Schleinkofer L, et al. Evidence of ex vivo and in vitro impaired neutrophil oxidative burst and phagocytic capacity in type 1 diabetes mellitus. Diabetes Res Clin Pract 1993; 19: 183–188.
25. Thomson GA, Fisher BM, Gemmell CG, et al. Attenuated neutrophil respiratory burst following acute hypoglycaemia in diabetic patients and normal subjects. Acta Diabetol 1997; 34: 253–256.
26. Wierusz-Wysocka B, Wysocki H, Siekierka H, et al. Evidence of polymorphonuclear neutrophils (PMN) activation in patients with insulin-dependent diabetes mellitus. J Leukoc Biol 1987; 42: 519–523.
27. Chanchamroen S, Kewcharoenwong C, Susaengrat W, et al. Human polymorphonuclear neutrophil responses to Burkholderia pseudomallei in healthy and diabetic subjects. Infect Immun 2009; 77: 456–463.
28. Delamaire M, Maugendre D, Moreno M, et al. [Exploration of the various steps of polymorphonuclear neutrophil function in diabetic patients]. J Mal Vasc 1995; 20: 107–112.
29. Tennenberg SD, Finkenauer R, Dwivedi A. Absence of lipopolysaccharide-induced inhibition of neutrophil apoptosis in patients with diabetes. Arch Surg 1999; 134: 1229–1233; discussion 1233–1234.
30. Sudo C, Ogawara H, Saleh AW, et al. Clinical significance of neutrophil apoptosis in peripheral blood of patients with type 2 diabetes mellitus. Lab Hematol 2007; 13: 108–112.
31. Spiller F, Carlos D, Souto FO, et al. alpha1-Acid glycoprotein decreases neutrophil migration and increases susceptibility to sepsis in diabetic mice. Diabetes 2012; 61: 1584–1591.
32. Advani A, Marshall SM, Thomas TH. Impaired neutrophil store-mediated calcium entry in Type 2 diabetes. Eur J Clin Invest 2004; 34: 43–49.
33. Nath N, Biswas S, Bhelwa A, et al. Plausible involvement of a diabetic serum factor in neutrophil membrane pathology. Indian J Biochem Biophys 1993; 30: 244–246.
34. Toivonen A, Kulmala P, Savola K, et al. Soluble adhesion molecules in preclinical type 1 diabetes. The Childhood Diabetes in Finland Study Group. Pediatr Res 2001; 49: 24–29.
35. Martin S. Soluble adhesion molecules in type 1 diabetes mellitus. Horm Metab Res 1997; 29: 639–642.
36. Nicoletti F, Conget I, Di MM, et al. Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2002; 45: 1107–1110.
37. Kretowski A, Kinalska I. L-selectin gene T668C mutation in type 1 diabetes patients and their first degree relatives. Immunol Lett 2000; 74: 225–228.
38. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004; 61: 481–497.
39. Lampeter ER, Kishimoto TK, Rothlein R, et al. Elevated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM. Diabetes 1992; 41: 1668–1671.
40. Yang XD, Michie SA, Mebius RE, et al. The role of cell adhesion molecules in the development of IDDM: implications for pathogenesis and therapy. Diabetes 1996; 45: 705–710.
41. Toivonen A, Kulmala P, Rahko J, et al. Soluble adhesion molecules in Finnish schoolchildren with signs of preclinical type 1 diabetes. Diabetes Metab Res Rev 2004; 20: 48–54.
42. Toivonen AM, Kimpimaki T, Kupila A, et al. Soluble adhesion molecules in young children with signs of beta-cell autoimmunity–prospective follow-up from birth. Diabetes Metab Res Rev 2006; 22: 176–183.
43. Toivonen AM, Kulmala P, Savola K, et al. Soluble adhesion molecules in pre-clinical Type 1 diabetes: a prospective study. Diabetologia 2003; 46: 492–495.
44. Linn T, Strate C, Federlin K, et al. Intercellular adhesion molecule-1 (ICAM-1) expression in the islets of the non-obese diabetic and low-dose streptozocin-treated mouse. Histochemistry 1994; 102: 317–321.
45. Somoza N, Vargas F, Roura-Mir C, et al. Pancreas in recent onset insulin-dependent diabetes mellitus. Changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor V beta usage, and cytokine profile. J Immunol 1994; 153: 1360–1377.
46. Ninova D, Dean PG, Stegall MD. Immunomodulation through inhibition of multiple adhesion molecules generates resistance to autoimmune diabetes in NOD mice. J Autoimmun 2004; 23: 201–209.
47. Yang XD, Karin N, Tisch R, et al. Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors. Proc Natl Acad Sci USA 1993; 90: 10494–10498.
48. Hasegawa Y, Yokono K, Taki T, et al. Prevention of autoimmune insulin-dependent diabetes in non-obese diabetic mice by anti-LFA-1 and anti-ICAM-1 mAb. Int Immunol 1994; 6: 831–838.
49. Scheynius A, Camp RL, Pure E. Reduced contact sensitivity reactions in mice treated with monoclonal antibodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1. J Immunol 1993; 150: 655–663.
50. Martin S, Rothe H, Tschope D, et al. Decreased expression of adhesion molecules on monocytes in recent onset IDDM. Immunology 1991; 73: 123–125.
51. Mysliwiec J, Kretowski A, Kinalski M, et al. CD11a expression and soluble ICAM-1 levels in peripheral blood in high-risk and overt type 1 diabetes subjects. Immunol Lett 1999; 70: 69–72.
52. Sampson MJ, Davies IR, Brown JC, et al. Monocyte and neutrophil adhesion molecule expression during acute hyperglycemia and after antioxidant treatment in type 2 diabetes and control patients. Arterioscler Thromb Vasc Biol 2002; 22: 1187–1193.
53. Grykiel K, Zozulinska D, Kostrzewa A, et al. [Evaluation of expression of polymorphonuclear neutrophil surface receptors in patients with type 1 diabetes]. Pol Arch Med Wewn 2001; 105: 377–381.
54. Advani A, Marshall SM, Thomas TH. Impaired neutrophil actin assembly causes persistent CD11b expression and reduced primary granule exocytosis in Type II diabetes. Diabetologia 2002; 45: 719–727.
55. Chello M, Mastroroberto P, Cirillo F, et al. Neutrophil-endothelial cells modulation in diabetic patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg 1998; 14: 373–379.
56. Segal AW. How neutrophils kill microbes. Annu Rev Immunol 2005; 23: 197–223.
57. Borregaard N, Sorensen OE, Theilgaard-Monch K. Neutrophil granules: a library of innate immunity proteins. Trends Immunol 2007; 28: 340–345.
58. Witko-Sarsat V, Rieu P, Descamps-Latscha B, et al. Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest 2000; 80: 617–653.
59. Zurawska-Plaksej E, Piwowar A, Knapik-Kordecka M, et al. Activities of neutrophil membrane-bound proteases in type 2 diabetic patients. Arch Med Res 2014; 45: 36–43.
60. Vengen IT, Dale AC, Wiseth R, et al. Lactoferrin is a novel predictor of fatal ischemic heart disease in diabetes mellitus type 2: long-term follow-up of the HUNT 1 study. Atherosclerosis 2010; 212: 614–620.
61. Kawabata K, Hagio T, Matsuoka S. The role of neutrophil elastase in acute lung injury. Eur J Pharmacol 2002; 451: 1–10.
62. Chua F, Laurent GJ. Neutrophil elastase: mediator of extracellular matrix destruction and accumulation. Proc Am Thorac Soc 2006; 3: 424–427.
63. Owen CA, Campbell MA, Sannes PL, et al. Cell surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. J Cell Biol 1995; 131: 775–789.
64. Piwowar A, Knapik-Kordecka M, Warwas M. Concentration of leukocyte elastase in plasma and polymorphonuclear neutrophil extracts in type 2 diabetes. Clin Chem Lab Med 2000; 38: 1257–1261.
65. Greer IA, Haddad NG, Dawes J, et al. Increased neutrophil activation in diabetic pregnancy and in nonpregnant diabetic women. Obstet Gynecol 1989; 74: 878–881.
66. Amaro A, Gude F, Gonzalez-Juanatey R, et al. Plasma leukocyte elastase concentration in angiographically diagnosed coronary artery disease. Eur Heart J 1995; 16: 615–622.
67. Saeed FA, Castle GE. Neutrophil chemiluminescence during phagocytosis is inhibited by abnormally elevated levels of acetoacetate: implications for diabetic susceptibility to infections. Clin Diagn Lab Immunol 1998; 5: 740–743.
68. Heilman K, Zilmer M, Zilmer K, et al. Arterial stiffness, carotid artery intima-media thickness and plasma myeloperoxidase level in children with type 1 diabetes. Diabetes Res Clin Pract 2009; 84: 168–173.
69. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995; 16: 21–26.
70. Cassatella MA. Neutrophil-derived proteins: selling cytokines by the pound. Adv Immunol 1999; 73: 369–509.
71. Tecchio C, Micheletti A, Cassatella MA. Neutrophil-derived cytokines: facts beyond expression. Front Immunol 2014; 5: 508.
72. Scapini P, Bazzoni F, Cassatella MA. Regulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophils. Immunol Lett 2008; 116: 1–6.
73. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1998; 14: 129–151.
74. Nerup J, Mandrup-Poulsen T, Helqvist S, et al. On the pathogenesis of IDDM. Diabetologia 1994; 37(Suppl 2): S82–S89.
75. Rabinovitch A, Suarez-Pinzon WL, Strynadka K, et al. Human pancreatic islet beta-cell destruction by cytokines involves oxygen free radicals and aldehyde production. J Clin Endocrinol Metab 1996; 81: 3197–3202.
76. Dominguez C, Ruiz E, Gussinye M, et al. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. Diabetes Care 1998; 21: 1736–1742.
77. Padgett LE, Broniowska KA, Hansen PA, et al. The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Ann N Y Acad Sci 2013; 1281: 16–35.
78. Hanifi-Moghaddam P, Schloot NC, Kappler S, et al. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 2003; 52: 1137–1142.
79. Wasserfall CH, Atkinson MA. Autoantibody markers for the diagnosis and prediction of type 1 diabetes. Autoimmun Rev 2006; 5: 424–428.
80. Perner A, Nielsen SE, Rask-Madsen J. High glucose impairs superoxide production from isolated blood neutrophils. Intensive Care Med 2003; 29: 642–645.
81. Zozulinska DA, Wierusz-Wysocka B, Wysocki H, et al. The influence of insulin-dependent diabetes mellitus (IDDM) duration on superoxide anion and hydrogen peroxide production by polymorphonuclear neutrophils. Diabetes Res Clin Pract 1996; 33: 139–144.
82. Segal AW, Dorling J, Coade S. Kinetics of fusion of the cytoplasmic granules with phagocytic vacuoles in human polymorphonuclear leukocytes. Biochemical and morphological studies. J Cell Biol 1980; 85: 42–59.
83. Rocha RE, Coelho I, Pequito DC, et al. Interval training attenuates the metabolic disturbances in type 1 diabetes rat model. Arq Bras Endocrinol Metabol 2013; 57: 594–602.
84. Uchimura K, Nagasaka A, Hayashi R, et al. Changes in superoxide dismutase activities and concentrations and myeloperoxidase activities in leukocytes from patients with diabetes mellitus. J Diabetes Complications 1999; 13: 264–270.
85. Pitozzi V, Giovannelli L, Bardini G, et al. Oxidative DNA damage in peripheral blood cells in type 2 diabetes mellitus: higher vulnerability of polymorphonuclear leukocytes. Mutat Res 2003; 529: 129–133.
86. Dincer Y, Akcay T, Ilkova H, et al. DNA damage and antioxidant defense in peripheral leukocytes of patients with Type I diabetes mellitus. Mutat Res 2003; 527: 49–55.
87. Wong RK, Pettit AI, Davies JE, et al. Augmentation of the neutrophil respiratory burst through the action of advanced glycation end products: a potential contributor to vascular oxidant stress. Diabetes 2002; 51: 2846–2853.
88. Inoue S, Lan Y, Muran J, et al. Reduced hydrogen peroxide production in neutrophils from patients with diabetes. Diabetes Res Clin Pract 1996; 33: 119–127.
89. Heinzelmann M, Mercer-Jones MA, Passmore JC. Neutrophils and renal failure. Am J Kidney Dis 1999; 34: 384–399.
90. Horio F, Fukuda M, Katoh H, et al. Reactive oxygen intermediates in autoimmune islet cell destruction of the NOD mouse induced by peritoneal exudate cells (rich in macrophages) but not T cells. Diabetologia 1994; 37: 22–31.
91. Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol 2011; 7: 691–699.
92. Diana J, Simoni Y, Furio L, et al. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med 2013; 19: 65–73.
93. Riyapa D, Buddhisa S, Korbsrisate S, et al. Neutrophil extracellular traps exhibit antibacterial activity against burkholderia pseudomallei and are influenced by bacterial and host factors. Infect Immun 2012; 80: 3921–3929.
94. Joshi MB, Lad A, Bharath PAS, et al. High glucose modulates IL-6 mediated immune homeostasis through impeding neutrophil extracellular trap formation. FEBS Lett 2013; 587: 2241–2246.
95. Jaillon S, Galdiero MR, Del PD, et al. Neutrophils in innate and adaptive immunity. Semin Immunopathol 2013; 35: 377–394.
96. van Gisbergen KP, Sanchez-Hernandez M, Geijtenbeek TB, et al. Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J Exp Med 2005; 201: 1281–1292.
97. Talukdar S, Oh DY, Bandyopadhyay G, et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med 2012; 18: 1407–1412.
98. Diana J, Lehuen A. Macrophages and beta-cells are responsible for CXCR2-mediated neutrophil infiltration of the pancreas during autoimmune diabetes. EMBO Mol Med 2014; 6: 1090–1104.
99. Willcox A, Richardson SJ, Bone AJ, et al. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009; 155: 173–181.
100. Lehuen A, Diana J, Zaccone P, et al. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 2010; 10: 501–513.
101. Haurogne K, Pavlovic M, Rogniaux H, et al. Type 1 diabetes prone NOD mice have diminished Cxcr1 mRNA expression in polymorphonuclear neutrophils and CD4+ T lymphocytes. PLoS One 2015; 10: e0134365.
102. Arif S, Moore F, Marks K, et al. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. Diabetes 2011; 60: 2112–2119.
103. Omi H, Okayama N, Shimizu M, et al. Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: effect of antidiabetic medicines. J Diabetes Complications 2002; 16: 201–208.
104. Okouchi M, Okayama N, Imai S, et al. High insulin enhances neutrophil transendothelial migration through increasing surface expression of platelet endothelial cell adhesion molecule-1 via activation of mitogen activated protein kinase. Diabetologia 2002; 45: 1449–1456.
105. Rawling LD, Advani A, Marshall SM, et al. Neutrophil antigen exposure is altered with age in relatives of patients with Type 2 diabetes. Diabetologia 2004; 47: 353–355.
106. Okayama N, Omi H, Okouchi M, et al. Mechanisms of inhibitory activity of the aldose reductase inhibitor, epalrestat, on high glucose-mediated endothelial injury: neutrophil-endothelial cell adhesion and surface expression of endothelial adhesion molecules. J Diabetes Complications 2002; 16: 321–326.
107. Hanninen A, Salmi M, Simell O, et al. Endothelial cell-binding properties of lymphocytes infiltrated into human diabetic pancreas. Implications for pathogenesis of IDDM. Diabetes 1993; 42: 1656–1662.
108. Itoh N, Hanafusa T, Miyazaki A, et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 1993; 92: 2313–2322.
109. Li N, Hu H, Lindqvist M, et al. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000; 20: 2702–2708.
110. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011; 11: 264–274.
111. Repka J, Nicoluzzi J, Belila R, et al. Neutrophil oxidative metabolism in diabetic patients undergoing pancreas transplantation. Transplant Proc 2006; 38: 3023–3025.
112. Hartz S, Menart B, Tschoepe D. Leukocyte apoptosis in whole blood involves platelet-dependent coaggregation. Cytometry A 2003; 52: 117–121.
113. Gawlowski T, Stratmann B, Stirban AO, et al. AGEs and methylglyoxal induce apoptosis and expression of Mac-1 on neutrophils resulting in platelet-neutrophil aggregation. Thromb Res 2007; 121: 117–126.
114. Jain SK, Krueger KS, McVie R, et al. Relationship of blood thromboxane-B2 (TxB2) with lipid peroxides and effect of vitamin E and placebo supplementation on TxB2 and lipid peroxide levels in type 1 diabetic patients. Diabetes Care 1998; 21: 1511–1516.
115. Renesto P, Chignard M. Enhancement of cathepsin G-induced platelet activation by leukocyte elastase: consequence for the neutrophil-mediated platelet activation. Blood 1993; 82: 139–144.
116. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405–412.
117. Hu H, Li N, Yngen M, et al. Enhanced leukocyte-platelet cross-talk in Type 1 diabetes mellitus: relationship to microangiopathy. J Thromb Haemost 2004; 2: 58–64.
118. Entman ML, Ballantyne CM. Association of neutrophils with platelet aggregates in unstable angina. Should we alter therapy. Circulation 1996; 94: 1206–1208.
119. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 103: 1718–1720.
120. Tuttle HA, Davis-Gorman G, Goldman S, et al. Platelet-neutrophil conjugate formation is increased in diabetic women with cardiovascular disease. Cardiovasc Diabetol 2003; 2: 12.
121. Baron JL, Reich EP, Visintin I, et al. The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between alpha 4-integrins and vascular cell adhesion molecule-1. J Clin Invest 1994; 93: 1700–1708.
122. Burkly LC, Jakubowski A, Hattori M. Protection against adoptive transfer of autoimmune diabetes mediated through very late antigen-4 integrin. Diabetes 1994; 43: 529–534.
123. Moriyama H, Yokono K, Amano K, et al. Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway. J Immunol 1996; 157: 3737–3743.
124. Dunne JL, Collins RG, Beaudet AL, et al. Mac-1, but not LFA-1, uses intercellular adhesion molecule-1 to mediate slow leukocyte rolling in TNF-alpha-induced inflammation. J Immunol 2003; 171: 6105–6111.
125. Oubenaissa A, Mouas C, Bourgeois F, et al. Evidence for an involvement of the neutrophil integrin lymphocyte function-associated antigen-1 in early failure of heart transplants. Circulation 1996; 94: II254–II259.
126. Basit A, Reutershan J, Morris MA, et al. ICAM-1 and LFA-1 play critical roles in LPS-induced neutrophil recruitment into the alveolar space. Am J Physiol Lung Cell Mol Physiol 2006; 291: L200–L207.
127. Forsyth KD, Levinsky RJ. Role of the LFA-1 adhesion glycoprotein in neutrophil adhesion to endothelium and plastic surfaces. Clin Exp Immunol 1989; 75: 265–268.
128. Asaduzzaman M, Zhang S, Lavasani S, et al. LFA-1 and MAC-1 mediate pulmonary recruitment of neutrophils and tissue damage in abdominal sepsis. Shock 2008; 30: 254–259.
129. Berton G, Laudanna C, Sorio C, et al. Generation of signals activating neutrophil functions by leukocyte integrins: LFA-1 and gp150/95, but not CR3, are able to stimulate the respiratory burst of human neutrophils. J Cell Biol 1992; 116: 1007–1017.